Angiotensin II-induced vascular dysfunction is mediated by the AT1A receptor in mice

Hypertension. 2004 May;43(5):1074-9. doi: 10.1161/01.HYP.0000123074.89717.3d. Epub 2004 Mar 8.

Abstract

Many of the actions of angiotensin II (Ang II) are mediated by angiotensin type 1 receptors (AT1), of which there are 2 pharmacologically indistinguishable subtypes (AT1A and AT1B). The purpose of this study was to evaluate the effect of an AT1A homozygous deletion (AT1A-/-) on vascular reactivity. AT1A-/- mice and control littermates (AT1A+/+) were infused with vehicle (saline) or Ang II (1000 ng x kg(-1) x min(-1)) for 7 days by osmotic pumps. Systolic pressure was increased in AT1A+/+ mice (Delta45+/-8 mm Hg, P<0.0001) but unchanged in AT1A-/- mice (Delta5+/-3 mm Hg, P>0.13) on day 7. The carotid artery response to the vasodilators acetylcholine (ACh), nitroprusside, and papaverine and to the vasoconstrictors phenylephrine, U46619, 5-hydroxytryptamine (5-HT), and KCl were not different between vehicle-infused AT1A+/+ and AT1A-/- animals. Carotid relaxation to ACh was impaired and contraction to 5-HT was increased in Ang II-infused AT1A+/+ mice. Ang II did not affect carotid responses in AT1A-/- mice. Superoxide, measured by lucigenin (5 micromol/L), and hydroethidine staining were not different between AT1A+/+ and AT1A-/- mice after vehicle or Ang II infusion, suggesting that it was not contributing to the altered ACh and 5-HT responses. The Rho-kinase inhibitor Y-27632 (1 micromol/L) attenuated the 5-HT response in both vehicle- and Ang II-infused AT1A+/+ mice. Moreover, concentration-dependent relaxation to Y-27632 and RhoA protein expression were not different in vehicle- or Ang II-infused AT1A+/+. These data demonstrate that the AT1A receptor is required for Ang II-induced changes in carotid artery function.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid / pharmacology
  • Acetylcholine / pharmacology
  • Amides / pharmacology
  • Angiotensin II / administration & dosage
  • Angiotensin II / toxicity*
  • Animals
  • Aorta / metabolism
  • Carotid Arteries / drug effects
  • Infusion Pumps, Implantable
  • Mice
  • Mice, Inbred C57BL
  • Mice, Knockout
  • Nitric Oxide / physiology
  • Nitroprusside / pharmacology
  • Papaverine / pharmacology
  • Phenylephrine / pharmacology
  • Potassium Chloride / pharmacology
  • Pyridines / pharmacology
  • Receptor, Angiotensin, Type 1 / biosynthesis
  • Receptor, Angiotensin, Type 1 / drug effects
  • Receptor, Angiotensin, Type 1 / genetics
  • Receptor, Angiotensin, Type 1 / physiology*
  • Receptor, Angiotensin, Type 2 / biosynthesis
  • Receptor, Angiotensin, Type 2 / genetics
  • Reverse Transcriptase Polymerase Chain Reaction
  • Sequence Deletion
  • Serotonin / pharmacology
  • Superoxides / metabolism
  • Vasoconstriction / drug effects*
  • Vasoconstriction / physiology
  • Vasoconstrictor Agents / pharmacology
  • Vasodilator Agents / pharmacology
  • rhoA GTP-Binding Protein

Substances

  • Amides
  • Pyridines
  • Receptor, Angiotensin, Type 1
  • Receptor, Angiotensin, Type 2
  • Vasoconstrictor Agents
  • Vasodilator Agents
  • Superoxides
  • Angiotensin II
  • Y 27632
  • Nitroprusside
  • Phenylephrine
  • Nitric Oxide
  • Serotonin
  • Potassium Chloride
  • 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid
  • Papaverine
  • rhoA GTP-Binding Protein
  • Acetylcholine